9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma

Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma

Estimated reading time: < 1 min

Condition: Pleural Malignant Mesothelioma

Estimated Enrollment: 14

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: 3-month PFS rate,  Estimate the distribution of progression-free and over survival,  ,

Interventions: GC1008,

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: October 2012

Completion Date: December 2014

Last  Posted Date: April 17, 2019

Location: Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Website Link: https://ClinicalTrials.gov/show/NCT01112293

Was this article helpful?
Dislike 0